We are primarily interested in technology development with a view to generation of biologics (peptides
and miniproteins) targeting dysfunctional p53 pathway components. In particular, we develop and employ
a range of directed evolution methodologies for protein engineering and selection. These approaches
are also being used to engineer/re-purpose enzymes for industrially relevant applications, with current
focus on development of “greener” enzyme alternatives for pharmaceutical synthesis. A further area
of interest is development of novel biosensing platforms, with emphasis on modular protein biosensors
for facile drug screening and diagnostic applications.
Farid J. Ghadessy - Group Leader
Siau Jia Wei
Chee Min Qi Sharon
Ng Aik Seng
Lau Sze Yi
Development and structural characterization of an engineered multi-copper oxidase reporter
of protein-protein interactions.
Sana B, Chee SMQ, Wongsantichon J, Raghavan S, Robinson RC,
J Biol Chem. 2019 Feb 15.
Synthetic 10FN3-based mono- and bivalent inhibitors of MDM2/X function.
Lau SY, Siau JW, Sobota RM, Wang CI, Zhong P, Lane DP,
Protein Eng Des Sel. 2018 Jul 1;31(7-8):301-312.
Structure-activity studies of Mdm2/Mdm4-binding stapled peptides comprising non-natural amino
acids. Chee SMQ, Wongsantichon J, Siau J, Thean D, Ferrer F, Robinson RC, Lane DP, Brown
PLoS One. 2017 Dec 11;12(12).
Development of a genetically programed vanillin-sensing bacterium for high-throughput screening
of lignin-degrading enzyme libraries. Sana B, Chia KHB, Raghavan SS, Ramalingam B, Nagarajan
N, Seayad J,
Biotechnol Biofuels. 2017 Feb 3;10:32.